Indocyanine green

Synaptive Medical Receives FDA 510(k) Clearance for Near-Infrared Fluorescence Visualization, Expanding Application of Existing Robotic Exoscope

Retrieved on: 
Wednesday, March 27, 2024
ICG, Diagnosis, MRI, Anatomy, Fluorescence, Neurosurgery, ENT, Indocyanine green, Lighting, LED, Blood, FDA, Food, Microscope

Near-Infrared fluorescence now available on Modus X robotic exoscope, complementing system’s existing advanced fluorescence capabilities

Key Points: 
  • Near-Infrared fluorescence now available on Modus X robotic exoscope, complementing system’s existing advanced fluorescence capabilities
    TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- Synaptive Medical Inc., a global med tech and technology company solving surgical, imaging and data challenges, has received 510(k) clearance from the Food and Drug Administration (FDA) for its Near-Infrared fluorescence visualization module, Modus IR, adding to the existing fluorescence offering on its 4K 3D robotic exoscope, Modus X.
  • Synaptive’s Modus X features a unique fluorescence feature, powered by customized LED lighting, that enables a live fusion of white light and fluorescence views.
  • This enables visualization of fluorescent tissue and surrounding anatomy simultaneously to provide additional anatomical context while performing complex microsurgical techniques.
  • ICG causes blood to fluoresce under infrared light and is used to aid in the visualization of vessels and blood flow.

A clearer vision for surgical robotics: CMR Surgical announces significant update to Versius

Retrieved on: 
Thursday, February 8, 2024
Surgeon, CMR, ICG, General surgery, 3D, Bose, Patient, Indocyanine green, CMR Surgical, Minimally invasive procedure, GMT, Contraindication, Communication, Thought, Sale, CE, Health, Eye, Gloucestershire Royal Hospital, Anatomy, MAS, Fatigue

CMR Surgical (CMR) – the global surgical robotics business – has today announced the launch of vLimeLite – an integrated fluorescence imaging system to visualise ICG (Indocyanine green), which will give surgeons enhanced visualisation, where indicated.

Key Points: 
  • CMR Surgical (CMR) – the global surgical robotics business – has today announced the launch of vLimeLite – an integrated fluorescence imaging system to visualise ICG (Indocyanine green), which will give surgeons enhanced visualisation, where indicated.
  • Supratim Bose, Chief Executive Officer of CMR Surgical, commented: “With 3D HD visualisation, surgeons already have a fantastic view of their operating field at our Versius console.
  • As long-term partners of CMR, we were delighted to be the first to get our hands on its ICG system.
  • Through the Versius Connect app, Versius Trainer and CMR clinical registry, Versius unleashes a wealth of insights to ultimately improve surgical care.

A clearer vision for surgical robotics: CMR Surgical announces significant update to Versius

Retrieved on: 
Thursday, February 8, 2024
Surgeon, CMR, ICG, General surgery, 3D, Bose, Patient, Indocyanine green, CMR Surgical, Minimally invasive procedure, GMT, Contraindication, Communication, Thought, Sale, CE, Health, Eye, Gloucestershire Royal Hospital, Anatomy, MAS, Fatigue

CMR Surgical (CMR) – the global surgical robotics business – has today announced the launch of vLimeLite – an integrated fluorescence imaging system to visualise ICG (Indocyanine green), which will give surgeons enhanced visualisation, where indicated.

Key Points: 
  • CMR Surgical (CMR) – the global surgical robotics business – has today announced the launch of vLimeLite – an integrated fluorescence imaging system to visualise ICG (Indocyanine green), which will give surgeons enhanced visualisation, where indicated.
  • Supratim Bose, Chief Executive Officer of CMR Surgical, commented: “With 3D HD visualisation, surgeons already have a fantastic view of their operating field at our Versius console.
  • As long-term partners of CMR, we were delighted to be the first to get our hands on its ICG system.
  • Through the Versius Connect app, Versius Trainer and CMR clinical registry, Versius unleashes a wealth of insights to ultimately improve surgical care.

Indocyanine Green Center-Stage at upcoming American College of Surgeons (ACS) Clinical Congress, October 2023, Boston, MA, USA

Retrieved on: 
Tuesday, September 19, 2023
Learning, Surgeon, Comparison, Gastrointestinal tract, Fluorescence, FGS, ACS, NIR, ICG, Medical imaging, Dentistry, Indocyanine green

FARMINGTON HILLS, Mich. , Sept. 19, 2023 /PRNewswire/ -- DIAGNOSTIC GREEN, the leading provider of Indocyanine Green (ICG) worldwide, is pleased to announce a day long training session on ICG as well as multiple other talks on ICG at the upcoming AMERICAN COLLEGE OF SURGEONS (ACS) Clinical Congress in Boston, MA, from October 22–25.

Key Points: 
  • FARMINGTON HILLS, Mich. , Sept. 19, 2023 /PRNewswire/ -- DIAGNOSTIC GREEN, the leading provider of Indocyanine Green (ICG) worldwide, is pleased to announce a day long training session on ICG as well as multiple other talks on ICG at the upcoming AMERICAN COLLEGE OF SURGEONS (ACS) Clinical Congress in Boston, MA, from October 22–25.
  • On Tuesday October 24th, a full day training course dedicated to fluorescence and ICG will be co-chaired by Dr Raul Rosenthal and Dr Sonia L. Ramamoorthy.
  • The training session is for surgeons and staff across all specialties interested in learning how to use near-infrared fluorescence modalities when conducting surgical procedures of the gastrointestinal tract and endocrine organs.
  • Also at the meeting, there are many other talks dedicated to FGS and the use of ICG across multiple surgical specialties.

Activ Surgical® Presented Findings from Colorectal Study Using its ActivSight™ Intelligent Light at the American Society of Colon and Rectal Surgeons Annual Scientific Meeting

Retrieved on: 
Monday, June 5, 2023
Technology, Surgery, Medical Devices, Hospitals, Health Technology, Software, Hardware, Health, Robotics, Ohio State University, Medicine, Surgeon, Laser speckle contrast imaging, Comparison, Rectum, Perfusion, Intelligent lighting, ASCRS, American Society of Colon and Rectal Surgeons, LOD, Doctor of Philosophy, Trial of the century, OSU, MD, Division, Ohio State University Wexner Medical Center, Patient safety, FDA, Society, ICG, Dissection, Medical imaging, Dentistry, Indocyanine green

Activ Surgical , a digital surgery pioneer, presented findings today at The American Society of Colon and Rectal Surgeons (ASCRS) Annual Scientific Meeting from a clinical study conducted at The Ohio State University Wexner Medical Center using the ActivPerfusion™ and ActivICG™ modes within its FDA cleared product, ActivSight™ Intelligent Light (ActivSight).

Key Points: 
  • Activ Surgical , a digital surgery pioneer, presented findings today at The American Society of Colon and Rectal Surgeons (ASCRS) Annual Scientific Meeting from a clinical study conducted at The Ohio State University Wexner Medical Center using the ActivPerfusion™ and ActivICG™ modes within its FDA cleared product, ActivSight™ Intelligent Light (ActivSight).
  • LSCI provides real-time tissue perfusion information by measuring coherent laser light scatter from moving red blood cells.
  • For cases where a decision was changed, the average discordance between the line of demarcation (LOD) in white light imaging and LSCI was 3.7cm.
  • “Less dissection and removal of tissue can improve patient safety and may lead to better surgical outcomes.”

Ferronova secures A$11 million to advance nanotech image-guided cancer therapy

Retrieved on: 
Sunday, January 22, 2023
Proton, University, Proton therapy, University of Sydney, Primary tumor, Royal Adelaide Hospital, Environment, Cancer, Artesian, Element, Surgeon, South Australian Health and Medical Research Institute, Research, Brain, Indocyanine green, Health, Patient, Lymph, University of South Australia, Pharmaceutical industry, Medical imaging, Renewal

Irish company Renew Pharmaceuticals Limited (Renew) led an A$8 million capital raise, with a further A$3 million secured via an Australian Government Co-operative Research Centers Project (CRC-P) grant.

Key Points: 
  • Irish company Renew Pharmaceuticals Limited (Renew) led an A$8 million capital raise, with a further A$3 million secured via an Australian Government Co-operative Research Centers Project (CRC-P) grant.
  • * Existing Ferronova shareholders, led by Uniseed with Artesian Venture Partners also participated.
  • The latest round of funding for the Adelaide, South Australian headquartered company builds on seed capital and Series A funding of $4.6 million.
  • Improvement in precision imaging, surgery, and therapy are now essential to improving long term outcomes.

Ferronova secures A$11 million to advance nanotech image-guided cancer therapy

Retrieved on: 
Sunday, January 22, 2023
Proton, University, Proton therapy, University of Sydney, Primary tumor, Royal Adelaide Hospital, Environment, Cancer, Artesian, Element, Surgeon, South Australian Health and Medical Research Institute, Research, Brain, Indocyanine green, Health, Patient, Lymph, University of South Australia, Pharmaceutical industry, Medical imaging, Renewal

Irish company Renew Pharmaceuticals Limited (Renew) led an A$8 million capital raise, with a further A$3 million secured via an Australian Government Co-operative Research Centers Project (CRC-P) grant.

Key Points: 
  • Irish company Renew Pharmaceuticals Limited (Renew) led an A$8 million capital raise, with a further A$3 million secured via an Australian Government Co-operative Research Centers Project (CRC-P) grant.
  • * Existing Ferronova shareholders, led by Uniseed with Artesian Venture Partners also participated.
  • The latest round of funding for the Adelaide, South Australian headquartered company builds on seed capital and Series A funding of $4.6 million.
  • Improvement in precision imaging, surgery, and therapy are now essential to improving long term outcomes.

Near Infrared Imaging Market Worth $2.81 Billion by 2030: Grand View Research, Inc.

Retrieved on: 
Thursday, January 19, 2023
Hospital, Clifton Springs Hospital & Clinic, National Research Universal reactor, ICG, Organic, Life expectancy, Research, Preclinical imaging, Diagnosis, Chronic kidney disease, Prevalence, Diabetes, International Agency for Research on Cancer, Patient, Indocyanine green, Degenerative disease, Revenue, SAN, Device, EUR, Dementia, Digital Writing and Research Lab, Alzheimer's disease, Disorder, Arthritis, USD, Higher School of Economics, CVD, NIR, Medical imaging, Economics, Cancer

SAN FRANCISCO, Jan. 19, 2023 /PRNewswire/ -- The global near infrared imaging market size is expected to reach USD 2.81 billion by 2030, registering a CAGR of 4.0% from 2022 to 2030, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Jan. 19, 2023 /PRNewswire/ -- The global near infrared imaging market size is expected to reach USD 2.81 billion by 2030, registering a CAGR of 4.0% from 2022 to 2030, according to a new report by Grand View Research, Inc.
  • Moreover, growing incidences of chronic disorders, especially among the geriatric population, are fueling industry growth.
  • Read 102-page market research report, " Near Infrared Imaging Market Size, Share & Trends Analysis Report By Product (Devices, Reagents), By Application (Cancer Surgeries, Preclinical Imaging), By End-use (Hospitals & Clinics, Research Labs), And Segment Forecasts, 2022 - 2030 ", published by Grand View Research.
  • Growing applications of NIR in commercial operations & research activities in biopharmaceutical companies as well as academic institutes are expected to drive the demand for advanced NIR systems in the coming years...
    Grand View Research has segmented the global near infrared imaging market based on product, application, end-use, and region
    NIR Imaging Market - Product Outlook (Revenue, USD Million, 2018 - 2030)

Near Infrared Imaging Market Worth $2.81 Billion by 2030: Grand View Research, Inc.

Retrieved on: 
Thursday, January 19, 2023
Hospital, Clifton Springs Hospital & Clinic, National Research Universal reactor, ICG, Organic, Life expectancy, Research, Preclinical imaging, Diagnosis, Chronic kidney disease, Prevalence, Diabetes, International Agency for Research on Cancer, Patient, Indocyanine green, Degenerative disease, Revenue, SAN, Device, EUR, Dementia, Digital Writing and Research Lab, Alzheimer's disease, Disorder, Arthritis, USD, Higher School of Economics, CVD, NIR, Medical imaging, Economics, Cancer

SAN FRANCISCO, Jan. 19, 2023 /PRNewswire/ -- The global near infrared imaging market size is expected to reach USD 2.81 billion by 2030, registering a CAGR of 4.0% from 2022 to 2030, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Jan. 19, 2023 /PRNewswire/ -- The global near infrared imaging market size is expected to reach USD 2.81 billion by 2030, registering a CAGR of 4.0% from 2022 to 2030, according to a new report by Grand View Research, Inc.
  • Moreover, growing incidences of chronic disorders, especially among the geriatric population, are fueling industry growth.
  • Read 102-page market research report, " Near Infrared Imaging Market Size, Share & Trends Analysis Report By Product (Devices, Reagents), By Application (Cancer Surgeries, Preclinical Imaging), By End-use (Hospitals & Clinics, Research Labs), And Segment Forecasts, 2022 - 2030 ", published by Grand View Research.
  • Growing applications of NIR in commercial operations & research activities in biopharmaceutical companies as well as academic institutes are expected to drive the demand for advanced NIR systems in the coming years...
    Grand View Research has segmented the global near infrared imaging market based on product, application, end-use, and region
    NIR Imaging Market - Product Outlook (Revenue, USD Million, 2018 - 2030)

Vergent Bioscience Awarded National Cancer Institute Phase 2 Grant to Advance Clinical Development of VGT-309 in Lung Cancer

Retrieved on: 
Tuesday, November 29, 2022
Oncology, Health, Surgery, Clinical Trials, Research, Science, Biotechnology, Indocyanine green, NCI, NIR, MIS, ICG, SBIR, University, National Cancer Institute, Stanford University School of Medicine, Patient, Neoplasm, Penn, Cardiothoracic surgery, Small business, Standard of care, Lung cancer, Thorax, Surgeon, Journal of Surgical Research, NIH, Research, Family, Cathepsin, Division, Trial of the century, Safety, Pharmaceutical industry, Medical imaging

Vergent Bioscience , a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that the National Cancer Institute (NCI) of the National Institutes of Health (NIH) has awarded the company a Small Business Innovation Research (SBIR) grant of nearly $2 million (Award Number R44CA277890).

Key Points: 
  • Vergent Bioscience , a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that the National Cancer Institute (NCI) of the National Institutes of Health (NIH) has awarded the company a Small Business Innovation Research (SBIR) grant of nearly $2 million (Award Number R44CA277890).
  • The grant will help fund a Phase 2 clinical study evaluating the companys targeted fluorescent imaging agent, VGT-309, for intraoperative imaging of tumors in patients undergoing lung cancer surgery.
  • We are grateful to the NCI for their support and to the team at the University of Pennsylvanias Perelman School of Medicine for conducting this Phase 2 study.
  • The company is first evaluating VGT-309 in lung cancer, with the potential to expand its application to a wide range of solid tumors.